Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Livermont T[original query] |
---|
Urine emtricitabine and tenofovir concentrations provide markers of recent antiretroviral drug exposure among HIV-negative men who have sex with men
Haaland RE , Martin A , Livermont T , Fountain J , Dinh C , Holder A , Lupo LD , Hall L , Conway-Washington C , Kelley CF . J Acquir Immune Defic Syndr 2019 82 (3) 252-256 BACKGROUND: Urine provides a minimally invasive specimen that may allow for development of rapid tests to detect antiretroviral drugs (ARVs) and provide opportunities to improve individual adherence. This study sought to determine if urine could provide a biomarker of adherence for currently approved PrEP and HIV treatment regimens. METHODS: Urine and blood were collected from 34 HIV-negative men who have sex with men aged 18-49 years enrolled in a clinical trial comparing 2 ARV regimens. Specimens were collected 4 and 24 hours after a single oral dose of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (n=10) or tenofovir alafenamide (TAF)/FTC/cobicistat (COBI)/elvitegravir (EVG) (n=8), or after 4 and 10 days of daily oral TDF/FTC (n=9) or TAF/FTC/COBI/EVG (n=7). Tenofovir (TFV), FTC, and EVG were measured by high performance liquid chromatography-mass spectrometry. RESULTS: Median urine FTC concentrations at 4 and 24 hours were similar between men receiving TDF/FTC (4 hours 147 microg/mL; 24 hours 10 microg/mL) and men receiving TAF/FTC/COBI/EVG (4 hours 333 microg/mL, p=0.173; 24 hours 13 microg/mL, p=0.681). Median urine TFV concentrations were lower among men receiving TAF/FTC/COBI/EVG (4 hours 1.2 microg/mL; 24 hours 0.8 microg/mL) compared to men receiving TDF/FTC (4 hours 17 microg/mL, p<0.001; 24 hours 7 microg/mL, p=0.001). Urine TFV concentrations remained reduced among men receiving TAF/FTC/COBI/EVG compared to men receiving TDF/FTC following daily dosing. EVG was not consistently measureable in urine. CONCLUSION: High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure